Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances [Yahoo! Finance]
Rocket Pharmaceuticals (RCKT) had its price target raised by The Goldman Sachs Group, Inc. from $2.00 to $3.00. They now have a "sell" rating on the stock.
Rocket Pharmaceuticals (RCKT) was upgraded by Lifesci Capital to "strong-buy".
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus [Yahoo! Finance]
Rocket Pharmaceuticals (RCKT) had its price target raised by Cantor Fitzgerald from $8.00 to $10.00. They now have an "overweight" rating on the stock.